Author Correction: Benralizumab vs Placebo in Hypereosinophilic Syndrome – What Changed?
What the Author Correction Means In October 2023, a pivotal phase 3 trial comparing benralizumab with placebo for hypereosinophilic syndrome (HES) was published. Shortly after, the…
Read More...
Read More...